Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 212

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 212
---
 financial statements.

 F-6

REVELATION BIOSCIENCES, INC. 

Consolidated Statements of Cash Flows

    Year EndedDecember 31,

    2024

    2023

    Cash flows from operating activities:

    Net loss
     
    $
    (15,038,536
    )

    (120,254
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Stock-based compensation expense

    168,850

    155,721

    Issuance of common stock for services

    25,000

    —

    Depreciation expense

    27,923

    25,049

    Change in fair value of warrant liability

    (81,441
    )

    (8,328,937
    )

    Changes in operating assets and liabilities:

    Prepaid expenses and other current assets

    17,992

    (11,559
    )

    Deferred offering costs

    71,133

    82,071

    Accounts payable

    (576,277
    )

    749,660

    Accrued expenses

    (2,935,920
    )

    161,963

    Net cash used in operating activities

    (18,321,276
    )

    (7,286,286
    )

    Cash flows from investing activities:

    Purchase of property and equipment

    (19,171
    )

    —

    Net cash used in investing activities

    (19,171
    )

    —

    Cash flows from financing activities:

    Proceeds from the February 2024 Public Offering, net

    5,417,053

    —

    Proceeds from the Class D Common Stock Warrants exercises

    241,390

    —

    Proceeds from Warrant Inducement exercises, net

    3,501,276

    —

    Proceeds from Class D Pre-Funded Warrants exercise

    127

    —

    Proceeds from the Class E Common Stock Warrants exercises

    3,687,918

    —

    Redemption of Series A Preferred Stock

    —

    (5,000
    )

    Proceeds from the February 2023 Public Offering, net

    —

    14,029,974

    Proceeds from Class C Pre-Funded Warrants exercise

    —

    34

    Net cash